The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Karin Walker Biography and Net Worth

CAO of Prothena

Ms. Walker has served as our Chief Accounting Officer since 2013. Prior to joining Prothena, she was Vice President, Finance and Chief Accounting Officer of Affymax, Inc., a position she held from 2012 to 2013. From 2009 to 2012, Ms. Walker was Vice President, Finance and Corporate Controller at Amyris Inc. From 2006 to 2009, she was Vice President, Finance and Corporate Controller for CV Therapeutics, Inc. Ms. Walker also held senior financial leadership positions at Knight Ridder Digital, Accellion, Niku Corporation, Financial Engines, Inc. and NeoMagic Corporation. Ms. Walker earned her B.S. in business from the California State Polytechnic University, San Luis Obispo, and is a certified public accountant.

What is Karin L. Walker's net worth?: The estimated net worth of Karin L. Walker is at least $72,350.00 as of July 17th, 2017. Ms. Walker owns 5,000 shares of Prothena stock worth more than $72,350 as of November 21st. This net worth estimate does not reflect any other investments that Ms. Walker may own. Learn More about Karin L. Walker's net worth.
How do I contact Karin L. Walker?: The corporate mailing address for Ms. Walker and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Karin L. Walker's contact information.
Has Karin L. Walker been buying or selling shares of Prothena?: Karin L. Walker has not been actively trading shares of Prothena within the last three months. Most recently, Karin L. Walker sold 5,000 shares of the business's stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $34.00, for a transaction totalling $170,000.00. Learn More on Karin L. Walker's trading history.
Who are Prothena's active insiders?: Prothena's insider roster includes Christopher Henney (Director), Carol Karp (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.
Are insiders buying or selling shares of Prothena?: During the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 15,000 shares worth more than $525,950.00. The most recent insider tranaction occured on January, 24th when CAO Karin L. Walker sold 5,000 shares worth more than $170,000.00. Insiders at Prothena own 28.2% of the company. Learn More about insider trades at Prothena.
Information on this page was last updated on 1/24/2024.

Karin L. Walker Insider Trading History at Prothena

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/24/2024	Sell	5,000	$34.00	$170,000.00
12/20/2023	Sell	5,000	$37.19	$185,950.00
11/30/2023	Sell	5,000	$34.00	$170,000.00
10/25/2023	Sell	5,000	$41.04	$205,200.00
9/19/2023	Sell	5,000	$52.36	$261,800.00
8/18/2023	Sell	5,000	$57.18	$285,900.00
7/19/2023	Sell	5,000	$69.19	$345,950.00
5/19/2023	Sell	5,000	$74.00	$370,000.00
4/19/2023	Sell	5,000	$52.90	$264,500.00
3/20/2023	Sell	5,000	$47.72	$238,600.00
3/15/2023	Sell	20,000	$48.42	$968,400.00
11/18/2022	Sell	10,000	$57.07	$570,700.00
10/24/2022	Sell	20,000	$57.23	$1,144,600.00
11/23/2021	Sell	4,519	$57.88	$261,559.72
10/20/2021	Sell	23,000	$60.25	$1,385,750.00
7/17/2017	Sell	5,000	$64.89	$324,450.00	5,000
4/17/2017	Sell	5,000	$52.25	$261,250.00	3,000
10/13/2016	Sell	5,000	$54.23	$271,150.00	3,000
9/19/2016	Sell	12,000	$61.10	$733,200.00	7,000
4/13/2016	Sell	4,000	$45.11	$180,440.00	2,000
1/13/2016	Sell	4,000	$50.96	$203,840.00
8/12/2015	Sell	7,000	$62.06	$434,420.00
8/12/2014	Sell	2,500	$20.74	$51,850.00
6/6/2014	Sell	8,000	$21.58	$172,640.00

Karin L. Walker Buying and Selling Activity at Prothena

Prothena Company Overview

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Today's Range

Now: $14.47

$14.19

$14.69

50 Day Range

MA: $17.79

$13.51

$22.11

2 Week Range

Now: $14.47

$13.22

$41.54

Volume

135,964 shs

Average Volume

581,098 shs

Market Capitalization

$778.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16

Financial Prophecy

From Porter & Company | Ad